CN1565536A - Cough stopping tablet of scutellariae and pig bile and its preparation method - Google Patents
Cough stopping tablet of scutellariae and pig bile and its preparation method Download PDFInfo
- Publication number
- CN1565536A CN1565536A CNA031338593A CN03133859A CN1565536A CN 1565536 A CN1565536 A CN 1565536A CN A031338593 A CNA031338593 A CN A031338593A CN 03133859 A CN03133859 A CN 03133859A CN 1565536 A CN1565536 A CN 1565536A
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- cough
- medicinal residues
- radix scutellariae
- armeniacae amarum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010011224 Cough Diseases 0.000 title claims abstract description 86
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 210000000941 bile Anatomy 0.000 title abstract 2
- 239000000843 powder Substances 0.000 claims abstract description 26
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 25
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 25
- 210000000582 semen Anatomy 0.000 claims description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- 239000000341 volatile oil Substances 0.000 claims description 39
- 235000014676 Phragmites communis Nutrition 0.000 claims description 33
- 210000000232 gallbladder Anatomy 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 241000218628 Ginkgo Species 0.000 claims description 24
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 24
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 18
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 14
- 238000005516 engineering process Methods 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 239000007921 spray Substances 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000009413 insulation Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000012047 saturated solution Substances 0.000 claims description 8
- -1 drying Substances 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 238000010411 cooking Methods 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 235000013717 Houttuynia Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 244000024873 Mentha crispa Species 0.000 abstract 1
- 235000014749 Mentha crispa Nutrition 0.000 abstract 1
- 244000018633 Prunus armeniaca Species 0.000 abstract 1
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract 1
- 241000951376 Schizonepeta tenuifolia Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 46
- 230000000694 effects Effects 0.000 description 38
- 206010062717 Increased upper airway secretion Diseases 0.000 description 31
- 208000026435 phlegm Diseases 0.000 description 31
- 210000004072 lung Anatomy 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 15
- 206010006458 Bronchitis chronic Diseases 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 206010006451 bronchitis Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 208000037656 Respiratory Sounds Diseases 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 208000007451 chronic bronchitis Diseases 0.000 description 10
- 239000003172 expectorant agent Substances 0.000 description 10
- 230000003419 expectorant effect Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 206010036790 Productive cough Diseases 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 206010037833 rales Diseases 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 206010044314 Tracheobronchitis Diseases 0.000 description 5
- 206010047924 Wheezing Diseases 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 4
- 230000000954 anitussive effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 229940124584 antitussives Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000009325 pulmonary function Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010044302 Tracheitis Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 208000008203 tachypnea Diseases 0.000 description 2
- 206010043089 tachypnoea Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a cough stopping tablet of scutellariae and pig bile and its preparation method, wherein the tablet comprises baikal skullcap root, pig bladder powder, cordate houttuynia, bitter apricot seed, root of ballon flower, ginkgo nut, Schizonepeta tenuifolia and spearmint.
Description
Technical field: the present invention is relevant at cough due to pathogenic wind-heat, abundant expectoration tachypnea or cough and tell rancid purulent sputum person, with the removing heat-phlegm that raw material of Chinese medicine such as Radix Scutellariae form, the medicine of lung qi dispersing cough-relieving, and the production technology of this Chinese patent medicine.
Background technology: one disease of treatment cough at present, all according to damp-phlegm, dry phlegm, the cause of disease that cold-phlegm etc. are different is drafted warming the lung for resolving phlegm respectively, removing heat from the lung and dissipating phlegm, the lung qi dispersing cough-relieving, astringing lung-QI and relieving cough is etc. method of treatment.But generally speaking dialectical not outer deficiency and excess two classes, cold and heat two guiding principles.And in the majority with the excess syndrome of lung-heat expectorant heap soil or fertilizer over and around the roots clinically, however the Chinese patent medicine of current this disease of treatment, and some emphasizes cough-relieving merely, reduce phlegm, relieving asthma, and ignored etiotropic treatment, be difficult to receive desirable curative effect, excess pathogen does not go, here does cough with asthma end? many medicines just adopt cough-relieving commonly used, reduce phlegm, and relieving asthma and wait the composition raw material to dispose, do not form good treatment lung-heat expectorant and stop up and cough suppressing medicine and tablet, more do not stretch into various proportioning raw materials and the effectively research of extraction composition.
Summary of the invention:
Purpose of the present invention will solve in treatment cough one disease exactly, should cough-relieving again to the technical problem of the treatment of the cause of disease, a kind of a kind of reed mentioned in ancient books gallbladder antitussive and tablet are provided, a kind of manufacturing process of a kind of reed mentioned in ancient books gallbladder antitussive is provided simultaneously.
A kind of reed mentioned in ancient books gallbladder antitussive of the present invention is got following raw material respectively: the Semen Ginkgo of the Semen Armeniacae Amarum of the Pulvis Fellis Suis of the Radix Scutellariae of 400-420 part, 15-25 part, the Herba Houttuyniae of 400-420 part, 400-420 part, the Radix Platycodonis of 200-220 part, 120-l40 part, the Herba Schizonepetae of 400-420 part, the Mentholum of 1.0-2.0 part by weight ratio.For a kind of a kind of reed mentioned in ancient books gallbladder cough stopping tablet, raw material contains the Radix Scutellariae of 400-420 part, the Pulvis Fellis Suis of 15-25 part, the Herba Houttuyniae of 400-420 part, the Semen Armeniacae Amarum of 400-420 part, the Radix Platycodonis of 200-220 part, the Semen Ginkgo of 120-140 part, the Herba Schizonepetae of 400-420 part, the Mentholum of 1.0-2.0 part by weight ratio.In the above-mentioned raw materials, 1. filtrate is boiled in the Radix Scutellariae water intaking, 2. Herba Schizonepetae is extracted volatile oil, 3. Herba Houttuyniae, Semen Armeniacae Amarum, Radix Platycodonis, Semen Ginkgo co-extracted volatile oil, 4. the water cooking liquid after extracting Herba Schizonepetae, Herba Houttuyniae, Semen Armeniacae Amarum, Radix Platycodonis, Semen Ginkgo medicinal residues and Radix Scutellariae medicinal residues behind the volatile oil and merging is used ethanol extraction with the merging of Radix Scutellariae decocting in water filtrate again, and 5. above-mentioned volatile oil, ethanol extraction, Pulvis Fellis Suis, Mentholum and appropriate amount of auxiliary materials are mixed and made into tablet.
A kind of reed mentioned in ancient books gallbladder cough stopping tablet preparation technology of the present invention gets following raw material respectively: 400-420 part Radix Scutellariae, 15-25 part Pulvis Fellis Suis, 400-420 part Herba Houttuyniae, 400-420 part Semen Armeniacae Amarum, 200-220 part Radix Platycodonis, 120-140 part Semen Ginkgo, 400-420 part Herba Schizonepetae, 1.0-2.0 part Mentholum by weight ratio;
(1) extraction of Radix Scutellariae: Radix Scutellariae added in the 8-10 times of water gaging carry out decocting 3 times, the time was respectively 30-90 minute, collecting decoction, and medicinal residues are standby; Decocting liquid filters, and filtrate is heated to 50 ± 2 ℃, stirs to add hydrochloric acid down and transfer pH value to 1-2, and 50 ± 2 ℃ of insulations are left standstill, and filter the taking-up precipitate, with hot wash to pH value 4, cold drying, filtrate for later use.
(2) Herba Schizonepetae adds 8 times of water gagings, keeps little boiling more than 3 hours, carries most volatile oil, and the aqueous solution after distillation device is in addition collected, and medicinal residues are standby; Herba Schizonepetae volatile oil beta-schardinger dextrin-inclusion;
(3) Herba Houttuyniae, Semen Armeniacae Amarum is ground into the coarse grain of 1/4-1/8, Radix Platycodonis, Semen Ginkgo powder is broken into the coarse grain of 1/2-1/4, Herba Houttuyniae, Semen Armeniacae Amarum, Radix Platycodonis, Semen Ginkgo powder extracts volatile oil, medicinal residues and Herba Schizonepetae medicinal residues behind the extraction volatile oil, the Radix Scutellariae medicinal residues merge, add water and fry in shallow oil secondary altogether, each more than 2 hours, the filtrate of (1) step that the filtrate of collecting decoction and other device are collected merges, relative density is 1.15 concentrated solution when being concentrated into 85 ℃, stir and to add ethanol down and make and contain determining alcohol and reach 60 ± 2%, leave standstill more than 24 hours, get the supernatant decompression recycling ethanol, relative density is 1.40 thick paste when being concentrated into 85 ℃, and vacuum drying below 60 ℃ becomes dried cream, is ground into the above fine powder of 80 orders.
(4) Pulvis Fellis Suis is ground into the above fine powder of 100 orders.
(5) above-mentioned three kinds of fine powders being added appropriate amount of auxiliary materials is mixed, make granule, dry, spray Mentholum alcoholic solution (Mentholum adds ethanol and makes saturated solution) is waved most ethanol in dried granule, add Herba Schizonepetae volatile oil β-CD inclusion complex mixing, spray into the volatile oil of Herba Houttuyniae, Semen Armeniacae Amarum, Radix Platycodonis, Semen Ginkgo again, tabletting, coating, packing.Each tablet is equivalent to crude drug in whole 2.02g.
On the basis of medicine pro-clinical trial phase of the present invention, through Ministry of Public Health audit approval, by clinical pharmacology base Affiliated Hospital of Nanjing University of Traditional Chinese Medicine---be above-mentioned five tame hospitals such as Jiangsu TCM Hospital's (for group leader unit) and Shandong Province Affiliated Hospital of university of TCM, press Ministry of Public Health and formulate clinical trial protocol about " the clinical research guideline of new drug (Chinese medicine) treatment chronic bronchitis " joint research, adopt double blind control (some cases is an open trial), observe case 420 examples altogether.Research finishes, and is broken jointly blind through the group leader unit of research institute and responsible checking, and wherein treatment group (the T group---take a kind of reed mentioned in ancient books gallbladder cough suppressing medicine, a kind of reed mentioned in ancient books gallbladder cough stopping tablet) 120 examples, show and control 90 examples (75%), total effective 109 examples (90.83%); Matched group (C group---qingfei yihuo sheet) 120 examples show control 46 examples (38.33%), total effective 82 examples (68.33%); Open group (O group---a kind of reed mentioned in ancient books gallbladder cough stopping tablet) 180 examples show control 156 examples (86.67%), total effective 173 examples (96.11%).Learn (Ridit) by statistics and analyze, the apparent control rate and the total effective rate of treatment group (T) and matched group (C) have significant differences, and the treatment group is better than matched group (R
T=0.3895, R
C=0.6105, U=5.9312, P＜0.01, for details see attached table 8=.
Clinical verification scheme according to a kind of reed mentioned in ancient books gallbladder cough stopping tablet, a kind of reed mentioned in ancient books gallbladder cough stopping tablet to Shandong Provincial Jiantong Hospital's development has carried out treatment cough syndrome of wind-heat invading lung, accumulation of phlegm-heat in the lung card (Western medicine diagnose acute tracheobronchitis, simple chronic bronchitis acute attack stage) double blind control has clinical trial, it observes case 80 examples (wherein acute tracheobronchitis 60 examples, simple chronic bronchitis acute attack stage 20 examples).40 examples are organized in treatment as a result, clinic control 18 examples (45%), and produce effects 14 examples (35%), 5 examples that take a turn for the better (12.5%), invalid 3 examples (7.5%) show control rate 80%, effective percentage 92.5%; Matched group 40 examples, clinic control 6 examples (15%), produce effects 9 examples (22.5%), 17 examples that take a turn for the better (42.5%), invalid 8 examples (20%) show control rate 37.5%, effective percentage 80%; Credit is analysed the treatment group and is better than matched group (P=0.0003) by statistics.
Table 1: each is organized patient and comes source distribution
Group example number patient source
Out-patient clinic and hospitalization X
2P
T 120 65 55 0.27 ＞0.05
C 120 69 51
O 180 113 67
Annotate: 1. P is accurate probability in the table, and relevant table together.
Statistical test refers to that all T group and C group compare.Each table together.
Table 2: each is organized patient's sex and distributes
Group example number sex
Men and women X
2P
T 120 63 57 0.017 ＞0.05
C 120 62 58
O 180 109 71
Table 3: each is organized patient age and distributes
Group example X in age several years ± SD scope
18～36～51～65 minima maximums
T 120 33 29 58 48.317±22.734 18 65
C 120 34 29 57 46.233±15.102 20 65
O 180 42 49 89 47.172±14.945 18 65
t＝0.584?P＞0.05
Table 4: each is organized patient's course of disease and distributes
Group example number course of disease R U P
＜3 3～ 6～ ＞10
T 120 60 21 19 20 0.5000
C 120 60 19 23 18 0.5000 0.0019 ＞0.05
O 180 90 27 22 41
Table 5: each is organized patient's state of an illness and distributes
Group example number state of an illness R U P
Heavy in light
T 120 12 78 30 0.4825
C 120 8 76 36 0.5175 0.9391 ＞0.05
O 180 14 108 58
Table 6: each is organized sick kind of patient and distributes
The sick X that plants of group example number
2P
An anxious chronic bronchitis
T 120 60 60 0 ＞0.05
C 120 60 60
O 180 90 90
Comprehensive above-mentioned analysis, treatment group (T) and matched group (C) case on sex, age, the course of disease and the state of an illness etc. distribute, all similar, there was no significant difference is so there is comparability.
Table 7: each organizes patient's tongue fur, pulse condition distributes
Group example number tongue fur pulse condition
The yellow greasy normal slick and frivolous number of red normal BOHUANG is normal
T 120 98 22 76 26 18 22 55 43
C 120 98 22 88 14 18 23 53 44
O 180 123 57 93 58 29 68 60 52
According to tongue fur, the analysis of pulse condition syndrome, meet wind-heat invading the lung and accumulation of phlegm-heat in the lung card.
[case selection]
One, disease
1. the traditional Chinese medical science: cough
2. doctor trained in Western medicine:
(1) acute tracheobronchitis
(2) chronic simple type bronchitis acute attack stage
Two, tcm syndrome differentiation and typing and diagnostic criteria:
1. syndrome of wind-heat invading lung: cough, Acute onset, paroxysm of cough or companion's aversion to cold, heating, nasal obstruction, yellow and thin fur, floating and rapid pulse.
2. accumulation of phlegm-heat in the lung card: cough, cough up phlegm, thick sputum or yellow pus, often be difficult for bringing up, thirsty, yellowish urine, big dry stool, red tongue, yellow fur, slippery and rapid pulse.
Three, Western medicine diagnose and standard
1. acute tracheobronchitis: (1) Acute onset; (2) clinical manifestation: cough, cough up phlegm (expectorant white or Huang or thickness band blood) or heating; (3) the thick or even news wheezing sound of auscultation of lung respiratory murmur, moist rale; Chest X-ray; Normal or enhanced lung markings; (4) chemical examination: increase at end hemogram total white blood cells or neutrality slightly.
2. simple chronic bronchitis acute attack stage: (1) clinical with cough, to cough up phlegm be that cardinal symptom or idol have and pant, annual morbidity continues 3 months, and continuous more than 2 years.In (2) 1 weeks purulence or mucopurulent sputum appear, amount of expectoration showed increased or with the performance of other inflammation; Or 1 cough in week, symptom such as expectorant any one aggravate to severe.
Four, diagnosis basis is worked out with reference to following document:
1. traditional Chinese medical science cough is with reference to Ministry of Public Health " new Chinese medicine clinical research guideline " and six editions teaching materials of " Chinese Internal Medicine " national unified editing.
2. the acute tracheobronchitis diagnostic criteria is with reference to " practical internal medicine " the 9th edition formulation.
3. the simple type acute episode of chronic bronchitis phase, diagnostic criteria is with reference to " new Chinese medicine clinical research guideline ".
Five, individual event symptom, severity extent grade scale reference " the clinical research guideline of new Chinese medicine treatment chronic bronchitis " etc.
1. heating:
Severe (+++): body temperature is more than 39 ℃;
Moderate (++): body temperature 38.1-39 ℃;
Slightly (+): body temperature 37.1-38 ℃;
Normally (-): body temperature is below 37 ℃.
2. cough
Negative (-): do not have cough.
Slightly (+): be interrupted cough daytime, do not influence orthobiosis and work.
Moderate (++): the cough symptom is heavier between slight (+) and severe (+++).
Severe (+++): cough round the clock frequent or apasm of coughing, influence rest or sleep.
3. cough up phlegm:
Amount of expectoration: do not have (-): no expectorant or 10ml round the clock.
Few (+): the 10-50ml that coughs up phlegm round the clock, or the 5-25ml that coughs up phlegm in night and early morning.
In (++): cough up 51-100ml round the clock, or the 26-50ml that coughs up phlegm in night and early morning.
Many (+++): above or night of the 100ml that coughs up phlegm round the clock and early morning cough up phlegm more than the 50ml.
4. pant:
Negative (-): do not have and pant.
Slightly (+): the idol of panting has outbreak, and degree is light, does not influence sleep or movable.
5. respiratory murmur is thick:
Do not have (-)
(+) arranged
6. wheezing sound:
Do not have (-)
(+) arranged: idol is heard, or occurs in cough, the dark fast back of breathing.
7. moist rale:
Do not have (-)
(+) arranged: hear reaching
(notes): according to these medicine characteristics pant herein, symptom and signs such as respiratory murmur is thick, wheezing sound, moist rale are divided into secondary score evaluation.
Six, comprehensive severe extent grade scale:
By above-mentioned standard: have one in the symptom and signs such as coughing, cough up phlegm for severe person is severe, have one for moderate person is a moderate, surplus is slight.
Seven, the test case is included standard in:
1. include standard in:
All acute tracheitiss (syndrome of wind-heat invading lung) that meets, chronic simple type bronchitis acute attack stage (accumulation of phlegm-heat in the lung card), body temperature be below 38.5 ℃, and the age is at 18-65 between year.All can include the test case in.
2. get rid of case standard (comprising inadaptation or rejecting standard).
(1) confirms on inspection by the patient that pants of the chronic cough due to the factors such as tuberculosis, fungus, tumor, irritative gas allergy.
(2) the concurrent serious emphysema cardiac insufficiency person of chronic bronchitis.
(3) be associated with serious primary disease such as cardiovascular, kidney, liver and hemopoietic system, psychotic.
(4) gestation or women breast-feeding their children are to this medicine allergy sufferers.
(5) all standards of including in that do not meet, not medication in accordance with regulations can't be judged that curative effect or data are complete and affects the treatment or safety judgement person.
[clinical trial protocol]
One, observe routine number: 300 examples are organized in treatment, and matched group 120 examples are counted 420 examples.(inpatient is no less than 1/3).
Two, observational technique: divide randomized controlled group and open group.Observe 120 pairs by 3 hospital's double blindings.90 examples (for open group O) are respectively observed by other 2 hospitals, among every group of patient, the severe case is no less than and observes 60% of routine number.
Three, observed content and recording method:, before and after treatment and in the therapeutic process, with symptom, sign, relevantly check and have no adverse reaction etc., at length fill in record immediately by the unified observation table of formulating.
Four, therapeutic scheme:
1. group technology:
Carry out double blind controling test (counting 120 pairs, totally 240 examples) by three medical institutions, its group technology is by " medical science number reason research statistical method " (People's Health Publisher's second edition in 1998, subordinate list 19 table of random numbers) inclined to one side at random number.Determine treatment group and matched group and sick kind distribution (seeing the disease kind and the grouped table of a kind of reed mentioned in ancient books gallbladder cough stopping tablet II clinical trial phase case for details).
2. medication:
(authentication code: ZZ-2404-defends in Tianjin No. [1996] 0946, the accurate word of medicine with a kind of reed mentioned in ancient books gallbladder cough stopping tablet (lot number 981212) and contrast medication qingfei yihuo sheet by drug development unit, lot number 981002), make the identical coated tablet dosage form of profile, specification and outer package, unified a kind of reed mentioned in ancient books gallbladder cough stopping tablet that is marked as, observe requirement by double-blind method, unified numbering is for clinical trial.
3. dosage:
The double blind control group is by random number clothes " a kind of reed mentioned in ancient books gallbladder cough stopping tablet ", one time 8, every day 2 times.(8 of each bag meters wherein have 2 to be the blank of no pharmaceutical compositions, because of the qingfei yihuo sheet is stipulated each 8, every day secondary).A kind of reed mentioned in ancient books gallbladder cough stopping tablet of every contains and is equivalent to crude drug in whole 2.02g.
Open group (also being the treatment group): at every turn obey 4 of a kind of reed mentioned in ancient books gallbladder cough stopping tablets, every day 3 times.
4. course of treatment:
7 days is a course of treatment.
Annotate: at treatment viewing duration, medicines such as not handy other relieving cough and resolving phlegm.
Five, observation index:
1. safety observation item:
(1) general body body project: (seeing the observation table).
(2) blood, urine routine test (each once also attached laboratory test report before and after the treatment)
(3) electrocardiogram, liver, kidney function test (open each 50 pairs of each units that organize)
2. health giving quality observation item:
(1) symptom: cough, cough up phlegm etc.;
(2) sign: pulmonary's respiratory murmur and rale, tongue fur, pulse condition etc.;
(3) other: chest x-ray, pulmonary function inspections such as (part unit are no less than 1/3);
Six, curative effect judging standard:
(1) foundation: work out with reference to " new drug Chinese medicine clinical research guideline "; Be divided into clinic control, produce effects, improvement, invalid level Four.
(2) curative effect determination methods: integration method
1. standards of grading: every sings and symptoms is divided into the level Four standard.
Weight person's (+++) is that 3 minutes, heavier person (++) are 2 minutes, are 1 minute than the lighter (+) that negative or disappear (-) is 0 minute.(this test is panted and pulmonary's body sheet is only marked by secondary).
2. each case individual event symptom and total effects are all judged by the percentage rate that sings and symptoms integrated value before and after the treatment changes.Promptly (treat preceding total mark value-treatment back total mark value)/the preceding total mark value of treatment * 100%.
90% above person is produce effects for facing control less than 90%-60% person, for taking a turn for the better, is invalid less than 60%-30% person below 30%.
Seven, the statistical disposition of clinical data:
It is used medicinal by research institute and group leader unit's open-blind, two groups of announcements that the test case is finished the back.
Clinical data according to collecting carries out appropriate statistical procedures to relevant data, and ranked data are checked with Ridit, and measurement data is checked with T, enumeration data X
2Check.
[result of the test]
One, respectively organizes the comprehensive total effects evaluation of patient
Table 8: each organizes patient's total effects analysis contrast
Efficacy evaluation
Group example digital display control rate (% total effective rate (R U P
It is invalid to face the improvement of control produce effects
T 120 40 50 19 11 75 90.83 0.3895
C 120 12 34 36 11 38.33 68.33 0.6105 5.9312 ＜0.01
O 180 93 63 17 7 86.67 96.11
Annotate: show control rate (%)=(facing control number+produce effects number)/checking total number of persons * 100%
Total effective rate (%)=(facing control number+produce effects number+improvement number)/checking total number of persons * 100% (relevant table together).
Learn to handle by statistics, treatment group (T) and matched group (C) show control rate and the total effects north significant difference of all rebelling party, and the treatment group is better than matched group.
Two, respectively organize patient's individual event symptom efficacy evaluation
Table 9: each organizes patient's individual event symptom Comparison of therapeutic
Efficacy evaluation
Symptom group example digital display control rate (% total effective rate (R U P
It is invalid to face the improvement of control produce effects
Heating T 37 31 033 83.78 91.89 0.4808
C 29 22 0 2 5 75.86 82.76 0.5246 0.6118 ＞0.05
O 125 118 1 6 0 95.2 100
Cough T 120 55 19 35 11 61.67 90.83 0.4069
C 120 23 10 59 28 27.5 76.67 0.5931 4.9976 ＜0.01
O 180 101 33 43 3 74.44 98.33
Expectorant T 120 64 10 30 16 61.67 86.67 0.4147
C 116 39 3 16 58 36.21 50 0.5882 4.6156 ＜0.01
O 170 124 7 38 9 77.06 94.71
Breathe heavily T 70 00 52 18 0 74.28 0.4523
C 69 0 0 38 31 0 55.07 0.5482 1.9617 ＜0.O5
O 124 0 0 100 24 0 80.64
Learn to handle by statistics, it is close that two groups of patients remove the curative effect of bringing down a fever, and outside the there was no significant difference, and cough-relieving, the curative effect of reducing phlegm, relieving asthma all have significant differences for two groups, and the cough-relieving of treatment group, the curative effect of eliminating the phlegm, relieving asthma are better than matched group.
Three, respectively organize the physical signs of patient efficacy evaluation
Table 10: each organizes the sign analysis contrast of patient pulmonary
Efficacy evaluation
Symptom group example digital display control rate (%) total effective rate (%) R U P
It is invalid to face the improvement of control produce effects
Breathe T 98 // 63 35/64.28 0.444
The thick C 92 of sound // 38 54/41.3 0.5593 2.7420＞0.01
O 160 / / 126 34 / 78.75
Wheezing sound T 30 // 26 4/86.66 0.4049
C 38 / / 20 18 / 52.63 0.5751 2.4131 ＜0.05
O 82 / / 72 10 / 87.80
Moist rale T 26 // 9 17/34.61 0.5013
C 17 / / 6 11 / 35.29 0.4979 0.0377 ＞0.05
O 74 / / 62 10 / 83.78
Learn to handle by statistics, improve treatment group curative effect and be better than the matched group (being respectively significant differences and significant difference) except that respiratory murmur slightly reaches wheezing sound, the improvement of moist rale, two groups of there was no significant differences then, curative effect is close.
Four, two groups of patient age and efficacy evaluation
Table 11: two groups of patient age and efficacy analysis contrast
Efficacy evaluation
Age (year) group example digital display control rate (%) total effective rate (%) R U P
It is invalid to face the improvement of control produce effects
18～35 T 33 12 12 5 4 72.73 87.88 0.4127
C 34 5 10 10 9 44.12 73.53 0.5847 2.7832 ＜0.01
O 42 31 8 2 1 92.86 97.62
36～50 T 29 14 7 4 4 72.41 86.21 0.4052
C 29 4 10 7 8 48.28 72.41 0.5948 2.5017 ＜0.05
O 49 33 12 4 1 91.84 97.96
51～65 T 58 14 31 10 3 77.59 94.83 0.3838
C 57 3 14 19 21 29.82 63.16 0.6434 4.5810 ＜0.01
O 87 29 43 12 5 82.76 94.25
Add up to T 120 40 50 19 11 75 90.83 0.3895
C 120 12 34 36 38 38.33 68.33 0.6105 5.9312 ＜0.01
O 180 93 63 17 7 86.67 96.11
Learn by statistics and handle, two groups of patients all have significant differences in the curative effect of each age group, and the treatment group all is better than matched group.
Five, respectively organize chronic bronchitis patient efficacy evaluation
Table 12: each organizes the chronic bronchitis patient course of disease and efficacy analysis contrast
Efficacy evaluation
The course of disease (year) group example digital display control rate (%) total effective rate (%) R U P
It is invalid to face the improvement of control produce effects
≤5 T 21 6 8 7 0 66.66 100 0.3792
C 19 0 7 6 6 36.84 68.42 0.6336 2.7832 ＜0.01
O 27 14 12 0 1 96.30 96.30
6～10 T 19 3 14 1 1 89.47 94.74 0.3145
C 23 1 7 4 11 34.78 52.17 0.6310 3.2346 ＜0.01
O 22 6 13 1 2 86.36 90.90
＞10 T 20 0 9 4 7 45 65 0.4618
C 18 2 0 10 6 11.11 66.66 0.5424 0.8589 ＞0.05
O 41 11 20 7 3 75.61 92.68
Add up to T 60 9 31 12 8 66.66 86.66 0.3938
C 60 3 14 20 23 28.33 61.66 0.6062 4.0293 ＜0.01
O 90 31 45 8 6 84.44 93.33
Learn by statistics and handle, two groups of chronic bronchitis patients have the significant difference in person's curative effect more than 10 years except that the course of disease, and the curative effect of all the other two course of disease sections all has significant differences, and the treatment group all is better than matched group.
Table 13: each organizes patient's state of an illness and efficacy analysis contrast
Efficacy evaluation
The state of an illness (year) group example digital display control rate (%) total effective rate (%) R U P
It is invalid to face the improvement of control produce effects
Light T 12 6510 91.67 100 0.4312
C 8 3 1 2 2 50 75 0.6031 1.3044 ＞0.05
O 14 11 2 0 1 92.86 92.86
Middle T 78 32 33 85 83.33 93.59 0.3784
C 76 8 25 25 18 43.42 76.32 0.6248 5.2951 ＜0.01
O 108 62 37 9 0 91.67 100
Heavy T 30 2 12 10 6 46.67 80 0.4116
C 36 2 7 9 18 25 50.00 0.5737 2.2076 ＜0.05
O 58 20 24 8 6 75.86 89.66
Add up to T 120 40 50 19 11 75 90.83 0.3895
C 120 13 33 36 38 38.33 68.33 0.6105 5.9312 ＜0.01
O 180 93 63 17 7 86.67 96.11
Learn to handle by statistics, two groups of patients except that the slight person's curative effect of the state of an illness close (no significant difference), severe person in its state of an illness, two groups of curative effects have been respectively significant differences and significant difference.The treatment group all is better than matched group.
Table 14: each is organized, and patient is sick to plant and the efficacy analysis contrast
Efficacy evaluation
Sick group example digital display control rate (%) total effective rate (%) the R U P that plants
It is invalid to face the improvement of control produce effects
An anxious T 60 31 19 73 83.33 95 0.3774
C 60 9 20 16 15 48.33 75.00 0.6226 4.6538 ＞0.01
O 90 62 18 9 1 88.89 98.89
Chronic bronchitis T 60 9 31 12 8 66.67 86.67 0.3938
C 60 3 14 20 23 28.33 61.67 0.6062 4.0293 ＜0.01
O 90 31 45 8 6 84.44 93.33
Add up to T 120 40 50 19 11 75 90.83 0.3895
C 120 12 34 36 38 38.33 68.33 0.6105 5.9312 ＜0.01
O 180 93 63 17 7 86.67 96.11
Learn by statistics and handle, anxious and chronic bronchitis, curative effect has significant differences between two groups, and the treatment group is better than matched group.
Six, two groups of treatment front and back tongue fur pulse conditions change
Table 15: tongue fur pulse analysis before and after two groups of patient
Controlling the back before controlling changes
The sign group is changeed natural rate of interest (%)
The positive common practice number of unusual routine number
Tongue T 98 26 26.53
C 98 20 20.41
O 123 110 89.43
Tongue T 102 29 28.43
C 102 27 26.47
O 151 131 86.75
Arteries and veins T 77 29 37.66
C 64 13 20.31
O 128 112 87.50
Through treatment, two groups of patients' tongue fur, pulse condition all have improvement in various degree, or it is normal to become a full member.
Seven, respectively organize patient's lab testing
Table 16: every laboratory indexes changed before and after each organized patient
Before and after the treatment of index group example number just, the unusual incidence rate of abnormal change changes natural rate of interest
Just/just/different/different/just (%) (%)
RBC T 97 95 0 0 2 0 100
C 98 90 0 5 3 0 37.5
O 180 159 4 3 3 2.45 50
WBC T 120 97 3 4 16 3.00 80
C 120 96 4 4 16 4 80
O 180 123 0 3 54 0 94.74
N T 120 76 5 15 23 6.17 60.53
C 120 74 13 11 22 14.94 66.67
O 180 58 5 27 90 7.94 76.92
Routine urinalysis T 80 72 0170 87.5
C 80 74 0 2 4 0 66.67
O 180 166 0 1 13 0 92.86
Liver function T 51 47 04000
C 50 0 0 0 50 0 100
O 104 99 0 1 0 0 0
Renal function T 51 51 00000
C 50 50 0 0 9 0 0
O 104 102 0 1 1 0 50
Annotate: just/just representing that the medication front and back are all normal; Just/different expression medication is preceding normal, and is unusual after the medication.Analogize.
Eight, pulmonary function
Table 17: pulmonary function (FVC, FV before and after two groups of patient
1%) change
Before controlling, index group example number controls back T
1T
2P
1P
2
X±SD X±SD
FVC T 39 2.582±1.070 2.955±1.028 5.919 0.359 ＜0.01 ＞0.05
(L) C 37 2.819±1.523 2.855±1.376 0.498 ＞0.05
O 67 2.405±0.949 2.712±0.824 5.397 ＜0.01
FV1 T 39 73.26±16.578 76.684±16.795 3.085 0.418 ＜0.01 ＞0.05
(％) C 37 72.753±16.869 78.117±12.558 2.535 ＜0.05
O 67 70.776±15.015 76.297±12.461 3.518 ＜0.01
Annotate: T
1, P
1Represent to compare before and after this group treatment
T
2, P
2Compare between the group of expression treatment back
Learn by statistics and handle, treatment group and open group FVC, FV
1%, all there is significant differences the treatment back before the treatment, before being better than after the treatment treating.FVC there was no significant difference before and after the treatment of control group, and FV
1There is significant difference % treatment back before the treatment, before being better than after the treatment treating.Compare FVC, FV between T, C group
1Difference that % treatment back changes that there are no significant.
Nine, change (T group+O group) before and after the treatment of X line and electrocardiogram
Before and after treating, table 18:X line and thought figure change
The treatment before and after just, abnormal change
The project example unusual incidence rate of number (%) is changeed natural rate of interest (%)
Just/just/different/different/just
X line 128 23 0 94 43 0 33.03
Electrocardio Figure 131 86 0 27 22 0 45.65
Annotate: the X ray examination refers to unusually: the lung stricture of vagina increases slightly, lung P and emphysema etc.
Electrocardioscopy refers to unusually: hole is slow, hole number left side chamber high voltage and T ripple or S-T section are slightly low flat or move down etc.
So compared with the prior art the present invention, has based on a large amount of removing heat-phlegm medicines, be aided with effective prescription of lung qi dispersing cough suppressing medicine treatment expectorant heat, cough due to pathogenic wind-heat.Making that heat clearing away is eliminating evil complements each other with relieving cough and asthma, bring out the best in each other, as guiding theory, and with reference to the design of ancient prescription, founded evident in efficacy, taking convenience, is " a kind of reed mentioned in ancient books gallbladder cough stopping tablet " of effect with removing heat-phlegm, lung qi dispersing cough-relieving.Be intended to convenient clinically, being convenient to patient that lung-heat expectorant stops up, to obey after heat eliminating evil clearly, and expectorant is turbid to be removed, and breathes with cough to such an extent that end, and lungs are from peace.To the cough tachypnea due to expectorant heat, the wind heat, abundant expectoration and gluing is difficult for diseases such as expectoration and has ideal curative effect.
Specific embodiment:
Embodiment one, a kind of a kind of reed mentioned in ancient books gallbladder cough stopping tablet of the present invention have Radix Scutellariae 417g, Pulvis Fellis Suis 20g, Herba Houttuyniae 417g, Semen Armeniacae Amarum 417g, Radix Platycodonis 208g, Semen Ginkgo 125g, Herba Schizonepetae 417g, Mentholum 1.7g, make 1000.Every contains and is equivalent to crude drug in whole 2.02g.
Preparation technology is as follows:
(1) extraction of Radix Scutellariae: Radix Scutellariae decocting 3 times (10,8,8 times of water gagings), the time was respectively 60,40,30 minutes, collecting decoction, medicinal residues are standby.Decocting liquid filters, and filtrate is heated to 50 ℃, stirs to add hydrochloric acid down and transfer pH value to 1-2, and 50 ℃ of insulations were left standstill 12 hours, made precipitation fully, filtration, precipitate with hot wash to pH value 4, cold drying, sieving makes into fine powder.
(2) Herba Schizonepetae adds 8 times of water gagings, is heated to and boils, and makes to keep little boiling 3 hours, carries most volatile oil, and the aqueous solution after distillation device is in addition collected, and medicinal residues are standby.Herba Schizonepetae volatile oil with beta-schardinger dextrin-with following technology inclusion: get β-CD and add water in right amount and make saturated solution, under 100 rev/mins mixing speed, (1ml: 8g) ratio drips volatile oil to the saturated aqueous solution of β-CD, under 45 ℃ of conditions of insulation, stirs inclusion 3 hours in oil: β-CD, be cooled to room temperature, put refrigerator cold-storage 24 hours (0-4 ℃), filter 40 ℃ of dryings, cross 60 mesh sieves, standby.
(3) Herba Houttuyniae, Semen Armeniacae Amarum (being ground into the coarse grain of 1/4-1/8), Radix Platycodonis, Semen Ginkgo (being ground into the coarse grain of 1/2-1/4) is extracted volatile oil, medicinal residues and Herba Schizonepetae medicinal residues behind the extraction volatile oil, the Radix Scutellariae medicinal residues merge, add water and fry in shallow oil secondary (8 times of water gagings for the first time altogether, 6 times of water gagings for the second time), each 2 hours, collecting decoction, filter, the medicinal liquid that filtrate and other device are collected merges, and being concentrated into relative density is the concentrated solution of 1.15 (85 ℃), adding ethanol under stirring makes and contains determining alcohol and reach 60%, left standstill 24 hours, and got the supernatant decompression recycling ethanol, being concentrated into relative density is the thick paste of 1.40 (85 ℃), 60 ℃ of vacuum dryings become dried cream, are ground into fine powder.
(4) Pulvis Fellis Suis is ground into fine powder.
(5) above-mentioned three kinds of fine powders are added appropriate amount of auxiliary materials, be mixed, make granule, drying, spray Mentholum alcoholic solution (Mentholum adds ethanol and makes saturated solution) is in dried granule, wave most ethanol, add Herba Schizonepetae volatile oil β-CD inclusion complex mixing, spray into Herba Houttuyniae, Semen Armeniacae Amarum, Radix Platycodonis, Semen Ginkgo volatile oil, tabletting, coating, packing promptly obtains a kind of reed mentioned in ancient books gallbladder cough stopping tablet.
1. animal acute toxicity test
The preliminary experiment mice gives medicine (do not add the even fine powder of all medicines of adjuvant before the film-making of a kind of reed mentioned in ancient books gallbladder cough stopping tablet, every gram is equivalent to crude drug in whole 9.4787g) 16g/kg, ig, and 10 none death of mice also do not have other poisoning manifestations.
In the maximum tolerance determination test, dosage reaches 16g/kgd, be about 300 times of clinical plan consumption, observe 7d after the administration continuously, compare with control group mice, feed, activity, stool, fur and various reflection are all no abnormal, two groups of none death of mice, more also no significant difference between the body weight gain group.Point out this medicine not have obvious acute toxicity effect, clinical plan consumption safety.
2. long-term toxicity test for animals
Rat gives a kind of reed mentioned in ancient books gallbladder cough stopping tablet 27g/kgd, 60d, (calculating 63 times that are equivalent to people's consumption to contain the crude drug amount) all do not have obvious influence to index such as the general situation hematology of rat, routine blood test, clotting time, platelet count and leukocyte differential count, blood biochemical, AST, ALT, ALP, BUN, Crea, TP, GLU, T-Bil, T-CHO, ALB and indexs such as urine and histopathology, point out this preparation not have obvious long term toxicity effect, clinical consumption of drafting and administration cycle safety.
3. Pharmacodynamic test of active extract
Medicine: do not add all fine drug powders of adjuvant before the film-making of a kind of reed mentioned in ancient books gallbladder cough stopping tablet, every gram is equivalent to crude drug in whole 9.4787g.
3.1 antitussive effect: mice and Cavia porcellus give a kind of reed mentioned in ancient books gallbladder cough stopping tablet (0.25g/kg, 0.52g/kg, 0.7g/kg; 0.22g/kg, 0.44g/kg) ig, ammonia and the caused cough of citric acid are shown tangible antagonism.
3.2 phlegm-dispelling functions: when the phenol red drainage method of mice laboratory observation gave a kind of reed mentioned in ancient books gallbladder cough stopping tablet 0.7g/kgig to mice, its trachea bright amount of phenol red output increased, and confirms that medicine has phlegm-dispelling functions.
3.3 bronchospasm, antiasthmatic effect: Cavia porcellus give a kind of reed mentioned in ancient books gallbladder cough stopping tablet 0.22g/kg, 0.44g/kg, to bronchospasm due to the histamine pant and ovalbumin due to bronchus anaphylaxis spasm all have tangible antagonism when the 0.44g/kg dosage.
3.4 antiinflammatory action: mice administration 0.52g/kg, 0.7g/kg, rat administration 0.2g/kg, 0.4g/kg have certain antagonism to acute exudative inflammation and chronic hyperplastic inflammation.
3.5 enhance immunity effect: mice nonspecific immunity and humoral immunization under 0.7g/kg dosage, are had facilitation.
3.6 0.7g/kg dosage has significant protective effect to the mice of pneumonia, reduces its mortality rate.
3.7 extracorporeal bacteria inhibitor test is the result show, medicine has bacteriostasis in 0.625 ‰ concentration to Hemolytic streptococcus; 1.25 ‰ concentration has bacteriostasis to staphylococcus aureus; 2.5 ‰ pair of Diplococcus pneumoniae has bacteriostasis.
Above result of the test prompting, this medicine is applicable to the cough of phlegm-heat obstructing in the lung, i.e. treatment of diseases such as acute tracheitis, pneumonia, allergic asthma.
Embodiment two, a kind of a kind of reed mentioned in ancient books gallbladder cough stopping tablet of the present invention and production technology
Raw material of Chinese medicine has Radix Scutellariae 400Kg, Pulvis Fellis Suis 24Kg, Herba Houttuyniae 403Kg, Semen Armeniacae Amarum 410kg, Radix Platycodonis 218kg, Semen Ginkgo 138kg, Herba Schizonepetae 410kg, Mentholum 1.2kg.
(1) extraction of Radix Scutellariae: Radix Scutellariae decocting 3 times (10,8,8 times of water gagings), the time was respectively 60,40,30 minutes, collecting decoction, medicinal residues are standby.Decocting liquid filters, and filtrate is heated to 50 ℃, stirs to add hydrochloric acid down and transfer pH value to 1-2, and 50 ℃ of insulations were left standstill 12 hours, made precipitation fully, filtration, precipitate with hot wash to pH value 4, cold drying, sieving makes into fine powder.
(2) Herba Schizonepetae adds 8 times of water gagings, is heated to and boils, and makes to keep little boiling 3 hours, carries most volatile oil, and the aqueous solution after distillation device is in addition collected, and medicinal residues are standby.Herba Schizonepetae volatile oil with beta-schardinger dextrin-with following technology inclusion: get β-CD and add water in right amount and make saturated solution, under 100 rev/mins mixing speed, (1ml: 8g) ratio drips volatile oil to the saturated aqueous solution of β-CD, under 45 ℃ of conditions of insulation, stirs inclusion 3 hours in oil: β-CD, be cooled to room temperature, put refrigerator cold-storage 24 hours (0-4 ℃), filter 40 ℃ of dryings, cross 60 mesh sieves, standby.
(3) Herba Houttuyniae, Semen Armeniacae Amarum are ground into the coarse grain of 1/4-1/8, and Radix Platycodonis, Semen Ginkgo powder are broken into the coarse grain of 1/2-1/4, extract volatile oil then.Medicinal residues behind the extraction volatile oil and Herba Schizonepetae medicinal residues, Radix Scutellariae medicinal residues merge, and add water and fry in shallow oil secondary (8 times of water gagings, 6 times of water gagings for the second time for the first time) altogether, each 2 hours, collecting decoction filtered, the medicinal liquid that filtrate and other device are collected merges, being concentrated into relative density is the concentrated solution of 1.15 (85 ℃), adds ethanol under stirring and makes and contain determining alcohol and reach 60%, leaves standstill 24 hours, get the supernatant decompression recycling ethanol, being concentrated into relative density is the thick paste of 1.40 (85 ℃), and 60 ℃ of vacuum dryings become dried cream, are ground into fine powder.
(4) Pulvis Fellis Suis is ground into fine powder.
(5) above-mentioned three kinds of fine powders are added appropriate amount of auxiliary materials, be mixed, make granule, drying, spray Mentholum alcoholic solution (Mentholum adds ethanol and makes saturated solution) is in dried granule, wave most ethanol, add Herba Schizonepetae volatile oil β-CD inclusion complex mixing, spray into the hair oil that Herba Houttuyniae, Semen Armeniacae Amarum, Radix Platycodonis, Semen Ginkgo are waved, tabletting, coating is packaged into a kind of reed mentioned in ancient books gallbladder cough stopping tablet.
Embodiment three, a kind of a kind of reed mentioned in ancient books gallbladder cough stopping tablet of the present invention and production technology
Raw material of Chinese medicine has Radix Scutellariae 410Kg, Pulvis Fellis Suis 16Kg, Herba Houttuyniae 413Kg, Semen Armeniacae Amarum 403Kg, Radix Platycodonis 208Kg, Semen Ginkgo 124Kg, Herba Schizonepetae 402Kg, Mentholum 1.9kg.
(1) extraction of Radix Scutellariae: Radix Scutellariae decocting 3 times (10,8,8 times of water gagings), the time was respectively 60,40,30 minutes, collecting decoction, medicinal residues are standby.Decocting liquid filters, and filtrate is heated to 50 ℃, stirs to add hydrochloric acid down and transfer pH value to 1-2, and 50 ℃ of insulations were left standstill 12 hours, made precipitation fully, filtration, precipitate with hot wash to pH value 4, cold drying, sieving makes into fine powder.
(2) Herba Schizonepetae adds 8 times of water gagings, is heated to and boils, and makes to keep little boiling 3 hours, carries most volatile oil, and the aqueous solution after distillation device is in addition collected, and medicinal residues are standby.Herba Schizonepetae volatile oil with beta-schardinger dextrin-with following technology inclusion: get β-CD and add water in right amount and make saturated solution, under 100 rev/mins mixing speed, (1ml: 8g) ratio drips volatile oil to the saturated aqueous solution of β-CD, under 45 ℃ of conditions of insulation, stirs inclusion 3 hours in oil: β-CD, be cooled to room temperature, put refrigerator cold-storage 24 hours (0-4 ℃), filter 40 ℃ of dryings, cross 60 mesh sieves, standby.
(3) Herba Houttuyniae, Semen Armeniacae Amarum (being ground into the coarse grain of 1/4-1/8), Radix Platycodonis, Semen Ginkgo (being ground into the coarse grain of 1/2-1/4) is extracted medicinal residues and the Herba Schizonepetae medicinal residues behind the volatile oil, the Radix Scutellariae medicinal residues merge, add water and fry in shallow oil secondary (8 times of water gagings for the first time altogether, 6 times of water gagings for the second time), each 2 hours, collecting decoction, filter, the medicinal liquid that filtrate and other device are collected merges, being concentrated into relative density is the concentrated solution of 1.15 (85 ℃), adds ethanol under stirring and makes and contain determining alcohol and reach 60%, leaves standstill 24 hours, get the supernatant decompression recycling ethanol, being concentrated into relative density is the thick paste of 1.40 (85 ℃), and 60 ℃ of vacuum dryings become dried cream, are ground into fine powder.
(4) Pulvis Fellis Suis is ground into fine powder.
(5) above-mentioned three kinds of fine powders are added appropriate amount of auxiliary materials, be mixed, make granule, drying, spray Mentholum alcoholic solution (Mentholum adds ethanol and makes saturated solution) is in dried granule, wave most ethanol, add Herba Schizonepetae volatile oil β-CD inclusion complex mixing, spray into Herba Houttuyniae, Semen Armeniacae Amarum, Radix Platycodonis, Semen Ginkgo volatile oil, tabletting, coating, packing promptly gets a kind of reed mentioned in ancient books gallbladder cough stopping tablet.
Claims (3)
1, a kind of a kind of reed mentioned in ancient books gallbladder cough stopping tablet is characterized in that: raw material contains 400-420 part Radix Scutellariae, 15-25 part Pulvis Fellis Suis, 400-420 part Herba Houttuyniae, 400-420 part Semen Armeniacae Amarum, 200-220 part Radix Platycodonis, 120-140 part Semen Ginkgo, 400-420 part Herba Schizonepetae, 1.0-2.0 part Mentholum by weight ratio.
2, as the said a kind of reed mentioned in ancient books gallbladder of claim 1 cough stopping tablet, it is characterized in that: 1. filtrate is boiled in the Radix Scutellariae water intaking, 2. Herba Schizonepetae is extracted volatile oil, 3. Herba Houttuyniae, Semen Armeniacae Amarum, Radix Platycodonis, Semen Ginkgo co-extracted volatile oil, 4. the water cooking liquid after extracting Herba Schizonepetae, Herba Houttuyniae, Semen Armeniacae Amarum, Radix Platycodonis, Semen Ginkgo medicinal residues and Radix Scutellariae medicinal residues behind the volatile oil and merging is used ethanol extraction with the merging of Radix Scutellariae decocting in water filtrate again, and 5. above-mentioned volatile oil, ethanol extraction, Pulvis Fellis Suis, Mentholum and appropriate amount of auxiliary materials are mixed and made into tablet.
3, a kind of a kind of reed mentioned in ancient books gallbladder cough stopping tablet preparation technology gets 400-420 part Radix Scutellariae, 15-25 part Pulvis Fellis Suis, 400-420 part Herba Houttuyniae, 400-420 part Semen Armeniacae Amarum, 200-220 part Radix Platycodonis, 120-140 part Semen Ginkgo, 400-420 part Herba Schizonepetae, 1.0-2.0 part Mentholum by weight ratio respectively;
(1) extraction of Radix Scutellariae: Radix Scutellariae added in the 8-10 times of water gaging carry out decocting 3 times, the time was respectively 30-90 minute, collecting decoction, and medicinal residues are standby; Decocting liquid filters, and filtrate is heated to 50 ± 2 ℃, stirs to add hydrochloric acid down and transfer pH value to 1-2, and 50 ± 2 ℃ of insulations are left standstill, and filter the taking-up precipitate, with hot wash to pH value 4, cold drying, filtrate for later use;
(2) Herba Schizonepetae adds 8 times of water gagings, keeps little boiling more than 3 hours, carries most volatile oil, and the aqueous solution after distillation device is in addition collected, and medicinal residues are standby; Herba Schizonepetae volatile oil beta-schardinger dextrin-inclusion;
(3) Herba Houttuyniae, Semen Armeniacae Amarum is ground into the coarse grain of 1/4-1/8, Radix Platycodonis, Semen Ginkgo powder is broken into the coarse grain of 1/2-1/4, Herba Houttuyniae, Semen Armeniacae Amarum, Radix Platycodonis, Semen Ginkgo powder extracts volatile oil, medicinal residues and Herba Schizonepetae medicinal residues behind the extraction volatile oil, the Radix Scutellariae medicinal residues merge, add water and fry in shallow oil secondary altogether, each more than 2 hours, the filtrate of (1) step that the filtrate of collecting decoction and other device are collected merges, relative density is 1.15 concentrated solution when being concentrated into 85 ℃, stir and to add ethanol down and make and contain determining alcohol and reach 60 ± 2%, leave standstill more than 24 hours, get the supernatant decompression recycling ethanol, relative density is 1.40 thick paste when being concentrated into 85 ℃, and vacuum drying below 60 ℃ becomes dried cream, is ground into the above fine powder of 80 orders;
(4) Pulvis Fellis Suis is ground into the above fine powder of 100 orders;
(5) above-mentioned three kinds of fine powders are added appropriate amount of auxiliary materials, be mixed, make granule, drying, spray Mentholum alcoholic solution (Mentholum adds ethanol and makes saturated solution) is in dried granule, wave most ethanol, add Herba Schizonepetae volatile oil β-CD inclusion complex mixing, spray into the volatile oil of Herba Houttuyniae, Semen Armeniacae Amarum, Radix Platycodonis, Semen Ginkgo, tabletting, coating, packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031338593A CN1273164C (en) | 2003-07-02 | 2003-07-02 | Cough stopping tablet of scutellariae and pig bile and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031338593A CN1273164C (en) | 2003-07-02 | 2003-07-02 | Cough stopping tablet of scutellariae and pig bile and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1565536A true CN1565536A (en) | 2005-01-19 |
| CN1273164C CN1273164C (en) | 2006-09-06 |
Family
ID=34470135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031338593A Expired - Lifetime CN1273164C (en) | 2003-07-02 | 2003-07-02 | Cough stopping tablet of scutellariae and pig bile and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1273164C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108404140A (en) * | 2016-06-01 | 2018-08-17 | 湖南安邦制药有限公司 | A kind of clathrate process of volatile oil |
-
2003
- 2003-07-02 CN CNB031338593A patent/CN1273164C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108404140A (en) * | 2016-06-01 | 2018-08-17 | 湖南安邦制药有限公司 | A kind of clathrate process of volatile oil |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1273164C (en) | 2006-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1850249A (en) | Composition with function of relieving cough and calming asthma and preparing method | |
| CN1212856C (en) | Medicine composition for treating sphagitis and preparing method thereof | |
| CN1799613A (en) | Chinese medicine for treating damp heat arthralgia and its preparation method | |
| CN1616014A (en) | Chinese medicine composition for treating diabetes and its preparing method | |
| CN1546090A (en) | Anticancer Chinese traditional medicine preparation and preparation process and application thereof | |
| CN1559519A (en) | Prunella spike extract and its preparation method and use | |
| CN100349598C (en) | Medicine for treating high lipemia and its production method | |
| CN1290553C (en) | Pharmaceutical composition for treating menorrhagia and method for preparing the same | |
| CN1879688A (en) | Preparation for treating wind-heat type cold, its preparation process and quality control method | |
| CN1712048A (en) | Traditional Chinese medicine for treating gas stagnation and stomach pain and preparation method thereof | |
| CN1323689C (en) | Medicine for treating prostatic accrementition and its preparation | |
| CN1579455A (en) | Composition of traditional Chinese medicine for large intestine hygropyretic disease and its preparation method | |
| CN101053566A (en) | Acetylcysteine or its salt and anti-infectious medicine composition | |
| CN1565536A (en) | Cough stopping tablet of scutellariae and pig bile and its preparation method | |
| CN1814260A (en) | Chinese medicine for treating blood stagnation disease | |
| CN1879706A (en) | 'Shuang Huang Lian' dispersible tablet and preparation method thereof | |
| CN1652805A (en) | A herbal composition for treating and improving bronchial dyspnea | |
| CN1650996A (en) | Medicinal composition, its preparation method and application | |
| CN1957999A (en) | Composition of Chinese traditional medicine, preparation method, and quality control method | |
| CN1772189A (en) | Auxiliary treating medicine for lung cancer in late stage | |
| CN1554407A (en) | Medicine for clearing away lung-heat, eliminating phaegn, reliveing cough and asthma and its preparing method | |
| CN1579531A (en) | Medicinal composition for treating anemopyretic cold and its preparation method | |
| CN1857609A (en) | Chinese medicine composition with nourishing health function and its preparing method | |
| CN1294925C (en) | Chinese medicine for treating hypertension and hyperlipemia and preparation thereof | |
| CN1238038C (en) | Medicine for tonifying kidney, strengthening spleen, replenishing esseuce and invigorating marrow and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: DALIAN ZHEN AO PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: ZHENAO PHARMACEUTICAL CO., LTD., DALIAN CITY |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 116620 Liaoning Dalian economic and Technological Development Zone double D port life all the way No. 88 Patentee after: Dalian Zhenao Pharmaceutical Co.,Ltd. Address before: 116620 Liaoning Dalian economic and Technological Development Zone double D port life all the way No. 88 Patentee before: DALIAN ZHEN-AO PHARMACEUTICAL Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060906 |
|
| CX01 | Expiry of patent term |